PVP Labs Invited to Present Taphalgin (Lumekefamide) at the 2026 Pain Therapeutics Summit Europe; Announces Key DEA Regulatory Determination
At PVP Labs, our mission has always been to pioneer safe, effective, and accessible solutions for pain management. Today, we are thrilled to share a major milestone in that journey. PVP Labs has been invited to present at the prestigious 2026 Pain Therapeutics Summit Europe, taking place in Amsterdam from May 7-8, 2026.
During the summit, our Chief Medical Officer, Joe Stauffer, DO, MBA, FAPCR, will deliver a presentation titled “Clinical & Regulatory Lessons from Taphalgin® (Lumekefamide).” This presentation will highlight the clinical efficacy of our first-in-class tetrapeptide analgesic and detail a recent, pivotal regulatory update that sets Taphalgin® apart in the landscape of pain therapeutics.
A Landmark DEA Determination
A central focus of Dr. Stauffer’s presentation will be a recent ruling from the U.S. Drug Enforcement Administration (DEA). In March 2026, the DEA completed a rigorous scientific review of the chemical structure of Lumekefamide under the definitions of the Controlled Substances Act (CSA).
The result? The DEA officially determined that Lumekefamide is not a controlled substance or a listed chemical under the CSA.
This determination is a profound market differentiator. By operating outside the regulatory constraints of traditional opioid scheduling, Taphalgin® is substantially de-risked. It eliminates the heavy administrative oversight, manufacturing constraints, and prescribing barriers that typically limit the commercial reach and patient accessibility of scheduled analgesics.
“The invitation to present our work at this prestigious summit is a profound honor,” said Eugene Zabolotsky, CEO of PVP Labs. “Our mission has always been to deliver potent pain relief without the systemic risks and regulatory burdens of conventional opioids. The DEA’s determination that Taphalgin® (Lumekefamide) is not a controlled substance validates our structural design and marks the beginning of a new chapter in safer, more accessible pain management.”
High-Potency Relief Without Opioid Liability
The acute pain market has long struggled with a difficult compromise: opioids remain the standard of care for severe pain, yet they carry high risks of addiction, dependence, and dangerous side effects like respiratory depression. Hospitals and military organizations desperately need safer, non-scheduled solutions that still provide quick, meaningful efficacy.
Taphalgin® (Lumekefamide) was engineered specifically to solve this problem. As an innovative, dual-mechanism analgesic, it utilizes selective μ1-opioid receptor agonism and N-type calcium channel modulation. This unique design delivers rapid analgesia – providing meaningful relief for acute post-operative pain within 15-30 minutes – while sparing the μ2-opioid receptors responsible for addiction, euphoria, and respiratory depression.
The safety profile of Taphalgin® is supported by over 100,000 documented human exposures. To date, there has been no recorded clinical evidence of euphoria, addiction, or respiratory depression events in pivotal trials or post-marketed experience.
Looking Ahead
With core intellectual property protected through 2036, our U.S. development strategy is focused on high-value initial markets, including acute pain, post-surgical care, military trauma, and veterinary medicine. The DEA’s non-scheduled designation allows for standard manufacturing and prescription workflows, removing the friction that has historically hindered the deployment of potent pain medications.
We look forward to sharing these insights and engaging with industry leaders at the Pain Therapeutics Summit Europe. This milestone validates our advanced peptide engineering platform and reinforces our commitment to transforming the future of pain management.
For more details, you can read our full press release on Business Wire.
About PVP Labs
PVP Labs is a clinical-stage biotechnology leader dedicated to the discovery and development of innovative peptide-based solutions. By leveraging translational science and advanced peptide engineering, the company is advancing a pipeline of safe and effective treatments for pain, wound care, and infectious diseases. Learn more at www.pvp-labs.com.
